Latest / Pharmacy Podcast Network / Collaborating with Maxor to Empower Specialty Pharmacy Patients and Providers | NASP Specialty Pharmacy Podcast
Transcript
- 0:05Speaker 1: You are listening to the global network of podcasters dedicated
- 0:09Speaker 1: to the pharmacy profession. Welcome to the Pharmacy Podcast Network.
- 0:25Speaker 2: You are listening to the NASP podcast. This Specialty Pharmacy
- 0:30Speaker 2: podcast is a collaboration with the National Association of Specialty
- 0:34Speaker 2: Pharmacy and the Pharmacy Podcast Network. The mission of the
- 0:37Speaker 2: National Association of Specialty Pharmacy is to improve specialty pharmacy
- 0:41Speaker 2: practice by promoting continuing professional education and certification of specialty
- 0:47Speaker 2: pharmacists while advocating for public policies that ensure patient access
- 0:51Speaker 2: to specialty medications. As the healthcare industry's leading podcasts dedicated
- 0:56Speaker 2: to the pharmacy profession, the Pharmacy Podcast Network is proud
- 1:00Speaker 2: to bring our listeners the NASP Podcast in collaboration with
- 1:04Speaker 2: the National Association of Specialty Pharmacy.
- 1:07Speaker 3: Well, my name is Sheila Arcatt, and I'm the President
- 1:09Speaker 3: and CEO of the National Association of Specialty Pharmacy. I
- 1:12Speaker 3: am delighted to welcome my very special guest to this
- 1:15Speaker 3: episode of the NASP podcast. Jesse Heaton Farm d MBA, CSP,
- 1:21Speaker 3: Vice President of Specialty and Infusion at maxhar and Michelle
- 1:24Speaker 3: mulgrew Farm d Vice President of Commercial Specialty Market Development
- 1:29Speaker 3: at Maxhor As the only independent provider of integrated pharmacy solutions,
- 1:34Speaker 3: Maxer has spent ninety nine years delivering seamless, patient centered care.
- 1:39Speaker 3: They blend every aspect of pharmacy strategy to create real,
- 1:44Speaker 3: measurable results while optimizing experiences for patients, customers, and members alike.
- 1:50Speaker 3: Maxer Specialty Pharmacy is redefining care for patients with rare
- 1:53Speaker 3: and orphan diseases. With a long history of comprehensive clinical
- 1:57Speaker 3: programs supporting many limit distribution drugs and their URAK Specialty
- 2:03Speaker 3: Pharmacy certification with Rare Disease Pharmacy Center of Excellence designation,
- 2:09Speaker 3: max Or Specialty Pharmacy specializes in providing exceptional, holistic care
- 2:14Speaker 3: for patients with rare diseases. Their high touch care with
- 2:17Speaker 3: customized care plans designed to meet the needs of the
- 2:20Speaker 3: individual patient, along with their rare disease expertise, allows them
- 2:25Speaker 3: to advocate for their patients and collaborate with providers, manufacturers, payers,
- 2:31Speaker 3: and other stakeholders to create custom treatment plans that result
- 2:35Speaker 3: in the best possible care. Jesse Heaton currently serves as
- 2:39Speaker 3: the Vice president of Specialty and Infusion at Maxor. With
- 2:42Speaker 3: over twenty years of pharmacy expertise in sixteen years dedicated
- 2:46Speaker 3: to home infusion and specialty pharmacy at Maxor, He has
- 2:50Speaker 3: successfully led Maxor's rare and orphan disease programs on a
- 2:53Speaker 3: national scale, which includes a heavy focus on cystic fibrosis.
- 2:58Speaker 3: His leadership extends to his establishing centers of excellence for
- 3:01Speaker 3: rare disease programs and home in fusion therapies in showcasing
- 3:05Speaker 3: a wealth of knowledge, an accreditation, payer and regulatory requirements
- 3:10Speaker 3: for clinical, specialty and infusion pharmacy services. Jesse has a
- 3:14Speaker 3: Doctor of Pharmacy degree from Texas Tech University Health Sciences
- 3:18Speaker 3: Center in Lubbock and an MBA in Healthcare from West
- 3:22Speaker 3: Texas A and M. Michelle mulgrew currently serves as the
- 3:26Speaker 3: Vice President of Commercial Specialty Market Development at Maxor, where
- 3:30Speaker 3: she is responsible for managing the specialty pipeline and securing
- 3:34Speaker 3: access to limited distribution drugs for specialty pharmacy patients. She
- 3:39Speaker 3: has nearly twenty years of experience in pharmacy services, with
- 3:42Speaker 3: over ten years focused on the specialty pharmacy space across
- 3:46Speaker 3: a wide variety of roles including specialty product management, business development,
- 3:52Speaker 3: pharmacy operations, and patient services. Michelle worked in retail pharmacy
- 3:57Speaker 3: and then in the pharmaceutical industry prior to beginning her
- 4:00Speaker 3: career in specialty pharmacy. She has a Doctor of Pharmacy
- 4:04Speaker 3: degree from Rutgers University and a certificate in Health Economics
- 4:08Speaker 3: and Outcomes Research from the University of Washington. Jesse and Michelle,
- 4:13Speaker 3: thanks so much for joining me today. So to start
- 4:16Speaker 3: off with Michelle and Jesse, how does specialty pharmacies collaborate
- 4:19Speaker 3: with other healthcare providers to provide comprehensive care for patients
- 4:23Speaker 3: with rare diseases.
- 4:26Speaker 4: That's a great question, Sheila, and thanks again for having
- 4:28Speaker 4: us here today. In understanding how specialty pharmacies collaborate, I
- 4:33Speaker 4: think it's important to recognize just how far pharmacy has
- 4:36Speaker 4: evolved in the past twenty years or so. Beyond the
- 4:40Speaker 4: advances we've seen in traditional specialty therapeutic areas, there's also
- 4:45Speaker 4: been a deeper understanding and advancement within the rare disease space. Ultimately,
- 4:50Speaker 4: we know that rare diseases are not that rare. There's
- 4:53Speaker 4: over seven thousand rare diseases affecting roughly thirty million Americans,
- 4:58Speaker 4: the majority of which do not have a cure yet.
- 5:02Speaker 4: This has driven much of the emerging developments in rare therapies,
- 5:06Speaker 4: as well as a rapidly evolving care landscape which has
- 5:10Speaker 4: ultimately redefined how we treat in care for our rare
- 5:14Speaker 4: disease patients. Part of that is navigating through the complexities
- 5:18Speaker 4: that rare disease patient's face, and a large component of
- 5:21Speaker 4: that is the collaboration and facilitation of care that specialty
- 5:26Speaker 4: pharmacies have with other healthcare providers such as physicians or nurses,
- 5:32Speaker 4: as well as having dedicated clinical teams with deep expertise
- 5:36Speaker 4: in rare diseases. We work cross functionally with multiple providers
- 5:40Speaker 4: so the specialty pharmacy can ensure proper care and timely
- 5:44Speaker 4: follow up is completed for our rare disease patients. We
- 5:48Speaker 4: call payers, providers, and other entities throughout multiple steps in
- 5:52Speaker 4: the process. Sometimes it's necessary to do this with patients
- 5:56Speaker 4: or caregivers live on the call to advocate on their
- 5:59Speaker 4: behalf and guide them through any questions or barriers. Specialty
- 6:04Speaker 4: pharmacies also have dedicated clinical pharmacists. We employee pharmacists that
- 6:09Speaker 4: are specially trained in rare diseases, who can consult with
- 6:12Speaker 4: positions on care plans that are tailored to patient goals
- 6:17Speaker 4: as well as dosage adjustments or potential side effects. The
- 6:21Speaker 4: specialty pharmacy manages complex medication regimens, assists with prior authorizations,
- 6:27Speaker 4: actively monitors patient response to treatment, and allows for timely
- 6:32Speaker 4: adjustments to care plans when necessary. So essentially, the specialty
- 6:36Speaker 4: pharmacy is acting as a central point of contact for
- 6:39Speaker 4: all aspects of the patient's rare disease management.
- 6:44Speaker 5: Adding to what Michelle has discussed, there are some additional
- 6:48Speaker 5: areas to consider as well. One area of opportunity could
- 6:51Speaker 5: be the support for genetic testing. When you consider that
- 6:55Speaker 5: rare disease patients already face up to five years on
- 6:58Speaker 5: average to receive an accurate diagnosis for their condition, a
- 7:02Speaker 5: rare disease specialty pharmacy is really well physicianed to help
- 7:06Speaker 5: navigate through any additional headwinds patients may face while onboarding
- 7:10Speaker 5: timely to a new therapy. One example of support could
- 7:14Speaker 5: be taken a proactive approach with genetic testing requirements, ensuring
- 7:19Speaker 5: that a payer requirements are identified up front and coordinated
- 7:23Speaker 5: with the physician could really help minimize unnecessary prior authorization
- 7:27Speaker 5: denials and even appills required in order to obtain approval.
- 7:33Speaker 5: Another area we see is support around drug and device coordination.
- 7:38Speaker 5: You know, with rare disease as well as many other
- 7:40Speaker 5: specialty therapies, drug and device coordination is important and should
- 7:45Speaker 5: really be prioritized. A pharmacy's clinical program can often be
- 7:49Speaker 5: intensely focused on the drugs, but the proper administration of
- 7:54Speaker 5: the medication can be just as important. Considering a self
- 7:58Speaker 5: administered injection or self confuse medication, or even when nebulized,
- 8:03Speaker 5: ensuring the proper device is selected in order to deliver
- 8:06Speaker 5: the proper dosage in the prescribed time is really critical
- 8:10Speaker 5: to ensure the patient is able to achieve optimal outcomes.
- 8:14Speaker 5: Not all nebulizers deliver the same particle size, for example,
- 8:18Speaker 5: or even concentration volume or administration time. Some products are
- 8:23Speaker 5: FDA approved as a drug device combination, so they've been
- 8:26Speaker 5: studied together and approved together, and some are not and
- 8:30Speaker 5: require additional clinical understanding to ensure the proper device selection.
- 8:35Speaker 5: This is really an area where I feel rare to
- 8:37Speaker 5: these pharmacies are experts in addressing these critical needs. Holistically
- 8:43Speaker 5: in building comprehensive clinical programs and to support patients.
- 8:49Speaker 4: And then tagging onto what Jessie just mentioned, if I
- 8:52Speaker 4: may add, specialty pharmacies work closely with healthcare providers such
- 8:57Speaker 4: as physicians, nurses, and keys managers to manage the treatment
- 9:01Speaker 4: of patients with rare disease, and this collaboration often involves
- 9:05Speaker 4: the coordination of care for patients and caregivers, so facilitating
- 9:10Speaker 4: communication between all parties to ensure that treatment plans are followed,
- 9:15Speaker 4: medications are dispensed correctly, and patient outcomes are monitored. As
- 9:20Speaker 4: a specialty pharmacy, we also provide educational resources to both
- 9:24Speaker 4: patients and healthcare providers about the disease and medications, including
- 9:28Speaker 4: side effects so what to look out for, how to mitigate,
- 9:32Speaker 4: as well as administration techniques. And of course, we also
- 9:35Speaker 4: provide adherence support things like counseling, customized reminders such as
- 9:39Speaker 4: the right method, right timing of drug administration, and sometimes
- 9:43Speaker 4: utilizing technology like apps or devices for medication management. We're
- 9:48Speaker 4: here to help patients adhere to complex treatment regimens.
- 9:54Speaker 5: It is true that we look to keep patients at
- 9:57Speaker 5: the center of all we do, but beyond the way
- 10:00Speaker 5: we support our patients in their journey. We also look
- 10:03Speaker 5: to build support to reduce the provider burden. Specialty pharmacies
- 10:07Speaker 5: can often take on some of the complex aspects of
- 10:09Speaker 5: managing rare to these patients, bringing up healthcare providers to
- 10:13Speaker 5: really focus on clinical decision making. Some areas of opportunity
- 10:18Speaker 5: for collaboration could include adherence monitoring. The specialty pharmacies are
- 10:22Speaker 5: well positioned for more frequent engagement with patients, regularly contacting
- 10:27Speaker 5: patients to evaluate medication adherents and proactively address any concerns
- 10:32Speaker 5: or challenges that they may have about their treatment that
- 10:37Speaker 5: could really prevent any potential gaps in therapy and the
- 10:40Speaker 5: potential for suboptimal outcomes that lead to unnecessary office physits
- 10:45Speaker 5: or hospitalizations. Another area could be prior authorization assistants. I
- 10:50Speaker 5: think most everyone listening to this conversation are well aware
- 10:54Speaker 5: of the prior authorization hurdles that prescribers and patients face
- 10:57Speaker 5: when initiating the new therapy. Gaining this complex process of
- 11:02Speaker 5: obtaining a prior authorization approval from the insurance company is
- 11:05Speaker 5: an area that I feel a specialty pharmacy can help
- 11:07Speaker 5: coordinate and set the patient and prescriber both up for
- 11:11Speaker 5: success from supporting the initiation of the pro authorization as
- 11:15Speaker 5: well as the frequent follow ups required to secure approval
- 11:19Speaker 5: in a timely manner for specialty medications. And then really lastly,
- 11:24Speaker 5: the real time communication. It's really another important area is
- 11:28Speaker 5: consistent in timely communication with both the patient and prescriber.
- 11:32Speaker 5: Ensuring the physician's team is aware of where the patient
- 11:35Speaker 5: is at in the journey can help reduce redundancies on
- 11:38Speaker 5: both the pharmacy and the physician's side and save valuable time.
- 11:43Speaker 5: An example could be utilizing electronic health records and secure
- 11:47Speaker 5: online portals in order to share patient information and treatment
- 11:51Speaker 5: updates with the physician and quickly.
- 11:55Speaker 4: Those are great points.
- 11:56Speaker 5: Jesse.
- 11:57Speaker 4: I think it's important to also mention the collaboration that
- 12:00Speaker 4: occurs between the specialty pharmacy and the manufacturer hub. So
- 12:05Speaker 4: one of the key parts of the patient journey where
- 12:08Speaker 4: we collaborate is with a manufacturer's hub and the coordination
- 12:12Speaker 4: that occurs between us. A lot of manufacturers offer a
- 12:16Speaker 4: variety of additional resources or support through their hub partner,
- 12:21Speaker 4: and one of the things that we do as a
- 12:23Speaker 4: specialty pharmacy is collaborate with that hub well in advance
- 12:27Speaker 4: of a manufacturer's drug launch to not only understand what
- 12:31Speaker 4: additional support or resources the hub will be offering, but
- 12:35Speaker 4: really working together to design a process that ensures the
- 12:38Speaker 4: most seamless experience for a patient to be connected to
- 12:42Speaker 4: those resources. We want our patients and their caregivers to
- 12:45Speaker 4: feel empowered and have all of the tools and support
- 12:49Speaker 4: they need to manage their condition.
- 12:52Speaker 3: Well. How do specialty pharmacies and sure patients have access
- 12:55Speaker 3: to the necessary medications for rare diseases, especially considering their
- 12:59Speaker 3: high cost and their limited availability.
- 13:05Speaker 4: There's several ways that we help our rare disease patients
- 13:08Speaker 4: access their medications. I think the biggest areas by far
- 13:11Speaker 4: are navigating through insurance coverage as well as patient assistance,
- 13:16Speaker 4: and that being said, the benefits investigation and verification for
- 13:21Speaker 4: insurance and drug coverage is a critical step and it
- 13:24Speaker 4: can often be the rate limiting step in the rare
- 13:26Speaker 4: disease patient journey. It's important to consider that, in addition
- 13:30Speaker 4: to drugs that are covered on the pharmacy benefit, there
- 13:34Speaker 4: are many drugs in the rare disease space that are
- 13:36Speaker 4: covered through the medical benefit and loosely speaking about half
- 13:41Speaker 4: of the rare disease pipeline are drugs that will potentially
- 13:44Speaker 4: sit within medical benefit coverage. That being said, being highly
- 13:48Speaker 4: fluent and navigating the PA process for pharmacy drugs as
- 13:52Speaker 4: well as the authorization process for medical drugs is critical
- 13:56Speaker 4: in ensuring the patient can access their medication as quickly
- 14:00Speaker 4: as possible. There's also the possibility of appeals. It's important
- 14:04Speaker 4: to understand that denials are not always a hard stop.
- 14:08Speaker 4: Having an understanding of the appeals process for that patient's
- 14:12Speaker 4: particular plan, such as what additional information needs to be submitted,
- 14:16Speaker 4: how it needs to be submitted, whether it's going to
- 14:19Speaker 4: be through electronic submission or appear to peer, what timeframe
- 14:23Speaker 4: are we working with for that appeal submission, as well
- 14:26Speaker 4: as how many levels of appeals there are and often
- 14:29Speaker 4: the specialty pharmacy can assist with this appeals process and
- 14:33Speaker 4: the extent of involvement can vary by a patient's plan.
- 14:39Speaker 3: So can you explain the process of risk stratification for
- 14:43Speaker 3: patients with rare diseases and how it impacts their treatment
- 14:46Speaker 3: plans and outcomes.
- 14:47Speaker 5: Certainly, when our team looks at risk ratification for rare
- 14:52Speaker 5: disease patients, using specialty medications. It largely serves as a
- 14:57Speaker 5: predictive analytics tool to identify potential officers cticles in a
- 15:00Speaker 5: patient's path that could prevent optimal clinical outcomes. These could
- 15:05Speaker 5: be associated with decreased physical functions, mental health, decline for
- 15:10Speaker 5: adherence to medication regimens, worsening health related quality of life,
- 15:15Speaker 5: more frequent hospitalizations, and potentially increase in healthcare costs. We
- 15:21Speaker 5: first look at risk ratification through initial assessment. Through this assessment,
- 15:26Speaker 5: we are evaluating patients based on clinical factors like disease
- 15:30Speaker 5: state and therapy complexity, homer abilities, patient accessibility should that
- 15:36Speaker 5: be vision or hearing challenges, or caregiver support needs, as
- 15:41Speaker 5: well as social determinants of health considerations. Patient engagement is
- 15:46Speaker 5: one of the most critical factors in delivering optimal patient care.
- 15:50Speaker 5: Understanding any communication preferences or barriers, any required caregiver support needs,
- 15:56Speaker 5: or other provider coordinations considerations can be bottle to ensuring
- 16:01Speaker 5: a successful patient journey. In our specialty pharmacy, we can
- 16:05Speaker 5: use this information gathered to stratify our patients into different
- 16:10Speaker 5: risk categories which can support the most appropriate patient engagement
- 16:14Speaker 5: requirements and resource allocation. If you have a patient maintaining
- 16:18Speaker 5: optimal compliance with positive patient reported outcomes, you may not
- 16:23Speaker 5: want to burden them with additional patient engagement. However, where
- 16:28Speaker 5: a patient with potential predictable risk factors associated with suboptimal compliance,
- 16:34Speaker 5: they might need to be placed on a more intensive
- 16:37Speaker 5: engagement pathway to set them up with improved opportunity to
- 16:40Speaker 5: achieve similar outcomes. Looking a little further at the impact
- 16:46Speaker 5: of ongoing treatment, you may see examples such as a
- 16:49Speaker 5: high risk patient. These patients could be patients that might
- 16:53Speaker 5: receive more intensive treatments or have a need for more
- 16:56Speaker 5: frequent follow ups. They could have had a recent worsening,
- 17:01Speaker 5: frequent misdays of school work, unplanned misses from activities that
- 17:07Speaker 5: are scheduled such as sporting event, or even hospitalizations. A
- 17:12Speaker 5: medium risk patient could be one that doesn't have any
- 17:17Speaker 5: observed condition worsening or maybe is not improving, but has
- 17:23Speaker 5: less negative screening metrics identified as a high risk patient,
- 17:27Speaker 5: and then you have a low risk patient. They might
- 17:29Speaker 5: be one more independent with their therapy while continuing to
- 17:33Speaker 5: maintain appropriate compliance with their therapy with little or no
- 17:36Speaker 5: negative screening factors. The risk stratification can lead to better
- 17:40Speaker 5: resource allocation and the ability to develop more personalized therapy
- 17:45Speaker 5: approaches and potentially better clinical outcomes by focusing care where
- 17:50Speaker 5: it's most needed, Identifying patient and therapy specific obstacles early on,
- 17:57Speaker 5: and then ongoing proactively helps set a pay up for
- 18:00Speaker 5: continuing success. And just to reiterate a couple of the
- 18:04Speaker 5: data elements not limited to, but including to our risk stratification.
- 18:10Speaker 5: You know, the miss days from work or school or
- 18:13Speaker 5: patient reported MYSS planned activities. A child not getting to
- 18:17Speaker 5: go to basketball after school or soccer game could be
- 18:21Speaker 5: a sign of a respector that we're identifying mental health screening,
- 18:26Speaker 5: physical health screening, any unmanaged disease related symptoms, adverse drug reaction,
- 18:33Speaker 5: hospitalization er or clinic visit increases.
- 18:39Speaker 3: That's fascinating. So, I mean that makes sense, right. The
- 18:41Speaker 3: more personalized you can make their treatment plan, the better
- 18:45Speaker 3: outcome they're going to have, right, because you're addressing their
- 18:47Speaker 3: individual challenges. Right.
- 18:51Speaker 5: Yeah. I think if you've seen one patient, sometimes you've
- 18:53Speaker 5: seen one patient, and so customizing your approach and being inflexible,
- 18:56Speaker 5: it's important to delivering personalized care for each of these
- 18:59Speaker 5: regises patient.
- 19:01Speaker 3: So we've talked about how expensive these therapies can be so,
- 19:04Speaker 3: can you elaborate on the types of patient support programs
- 19:07Speaker 3: that are available through specialty pharmacies for those who have
- 19:11Speaker 3: rare and orphan diseases.
- 19:16Speaker 5: Rare disease patient therapies can be complex and patients can
- 19:20Speaker 5: benefit from a wide variety of support that may not
- 19:23Speaker 5: always be directly associated with the medication, but can be
- 19:26Speaker 5: just as important to ensure success with the prescribed therapy.
- 19:30Speaker 5: While we strive to do extraordinary things, you know, we
- 19:33Speaker 5: pride ourselves on doing the simple things extraordinarily well. Beyond
- 19:38Speaker 5: financial assistance that helps ensure patients can access their medications,
- 19:42Speaker 5: whether that be manufacturer or foundation assistants, they are also
- 19:47Speaker 5: ample resources for both patients and caregivers. We provide up
- 19:52Speaker 5: front a dedicated case manager that is aligned with both
- 19:55Speaker 5: the patient and the prescriber. This is to connect with
- 20:00Speaker 5: additional programs that are relevant to their specific disease state
- 20:03Speaker 5: and their specific treatment, as well as any outside resources
- 20:07Speaker 5: to help mitigate any challenges or barriers that may arise
- 20:10Speaker 5: through the assessment process or ongoing on therapy. This really
- 20:14Speaker 5: ties back to what we discussed earlier around optimizing the
- 20:17Speaker 5: approach with communication or our patients.
- 20:23Speaker 4: Well said Jessie, I would also like to add that
- 20:26Speaker 4: in our engagement with patients, we do have a unique
- 20:29Speaker 4: opportunity to bring awareness to the various resources that are available.
- 20:34Speaker 4: We can link patients and caregivers to things like educational
- 20:37Speaker 4: programs such as workshops, one on one sessions, or online
- 20:41Speaker 4: modules about living with their condition, as well as psychological
- 20:46Speaker 4: support resources like counseling services or support groups to help
- 20:50Speaker 4: manage the emotional toll and isolation that rare disease patients
- 20:55Speaker 4: can experience. And then going back to the question around
- 21:00Speaker 4: on the high cost of the medications, I think it's
- 21:02Speaker 4: also important to understand what financial resources are available and
- 21:07Speaker 4: specialty pharmacies are well positioned to be able to offer
- 21:10Speaker 4: that to our rare disease patients. So many drugs have
- 21:13Speaker 4: a copay card that can be applied to patients with
- 21:16Speaker 4: commercial insurance that can significantly bring down the out of
- 21:20Speaker 4: pocket costs for patients that have a high copay even
- 21:24Speaker 4: after approval. And beyond that, there are five oh one
- 21:27Speaker 4: C three foundations that offer grants to help offset a
- 21:31Speaker 4: patient's cost. These programs can vary by amount available and
- 21:35Speaker 4: also by diagnosis and then understanding the timing of when
- 21:39Speaker 4: grant funds become available or refreshed or renewed is important
- 21:44Speaker 4: for successfully securing copay assistance for a patient. And then
- 21:48Speaker 4: if all options are exhausted, many manufacturers have a free
- 21:52Speaker 4: drug program that can utilize as the last resort. The
- 21:55Speaker 4: qualifications for these programs can vary based on a variety
- 21:58Speaker 4: of factors, so it's important for a patient assistants team
- 22:02Speaker 4: to be aware of the requirements.
- 22:07Speaker 3: So, Michelle, as we look into our crystal ball, what
- 22:10Speaker 3: future trends do you first see in the field of
- 22:12Speaker 3: rare disease treatment and how do you think these will
- 22:14Speaker 3: impact the role that specialty pharmacies play like in the
- 22:18Speaker 3: next decade or so.
- 22:20Speaker 4: Sure, so, I believe that we can expect a significant
- 22:24Speaker 4: rise and personalized gene therapies, advanced cell therapies as well
- 22:28Speaker 4: as targeted therapies, leading to a more prominent role for
- 22:32Speaker 4: specialty pharmacies in managing complex treatment regimens, providing extensive patient support,
- 22:39Speaker 4: and navigating through intricate reimbursement models for these high cost medications,
- 22:43Speaker 4: really with a focus on patient education and adherance to
- 22:47Speaker 4: ensure optimal outcomes. So, thinking about the gene and cell
- 22:50Speaker 4: therapies currently available, but also in the pipeline. I think
- 22:54Speaker 4: there's about over thirty selling gene therapies currently approved in
- 22:58Speaker 4: the US, more expected by the end of this year,
- 23:02Speaker 4: and I think more than ninety by twenty thirty one.
- 23:06Speaker 4: As gene therapies become more readily available for a wider
- 23:10Speaker 4: range of rare diseases, specialty pharmacies will need to develop
- 23:14Speaker 4: expertise in handling these complex medications, including specialized storage, handling,
- 23:19Speaker 4: administration protocols, and especially patient monitoring post treatment. Now from
- 23:25Speaker 4: a clinical perspective, with the rise of personalized medicine within
- 23:29Speaker 4: the rare disease space, specialty pharmacies will have a greater
- 23:33Speaker 4: opportunity to tailor treatment plans based on individual patient genetic profiles,
- 23:39Speaker 4: not only requiring advanced clinical knowledge, but also having that
- 23:43Speaker 4: close collaboration with healthcare providers and then thinking about the
- 23:47Speaker 4: administration of these medications. Many new rare disease treatments will
- 23:51Speaker 4: involve intricate administrations, schedules, and protocols that may require robust
- 23:57Speaker 4: patient support services beyond patient and caregiver education, but also
- 24:02Speaker 4: medication adherence programs remote monitoring, all things which specialty pharmacies
- 24:08Speaker 4: are well positioned to provide, and then to add to that,
- 24:11Speaker 4: there's also more opportunity for the advancement of digital health
- 24:15Speaker 4: tools for monitoring and patient care. Many digital tools can
- 24:19Speaker 4: be customized to a specific therapeutic area or drug, not
- 24:24Speaker 4: only making the interactions more relevant and meaningful for a patient,
- 24:28Speaker 4: but also allowing for a patient or a caregiver to
- 24:31Speaker 4: feel supported in having the tools that they need to
- 24:34Speaker 4: manage their condition and then thinking in parallel to all
- 24:38Speaker 4: of these advancements, it's also important to understand the impact
- 24:41Speaker 4: of any regulatory changes on the horizon, such as any
- 24:45Speaker 4: new regulations or insurance models which may affect FRUM pricing, distribution,
- 24:50Speaker 4: and patient access.
- 24:55Speaker 3: So, jess what advice would you give to other pharmacists
- 24:58Speaker 3: and healthcare leaders who look to improve their support for
- 25:01Speaker 3: patients with where and orphan diseases.
- 25:05Speaker 5: Thanks Sheila with the growing rare disease pipeline mush, I'll
- 25:09Speaker 5: alluded to. I think understanding the constantly changing environment and
- 25:15Speaker 5: manufacturer of product support needed requires a constant state of
- 25:19Speaker 5: continuous learning, keeping up with the latest research, pipeline treatments,
- 25:24Speaker 5: and patient and products support strategies needed in the rare
- 25:27Speaker 5: disease space goes beyond just the clinical support of the
- 25:30Speaker 5: drug itself. Build networks, So establishing a strong relationship with
- 25:37Speaker 5: industry partners, patient advocacy groups, and other stakeholders in the
- 25:41Speaker 5: rare disease community. Patient advocacy groups and the rare disease
- 25:45Speaker 5: can be a really undervalued partner and helping all stakeholders
- 25:50Speaker 5: involved understand any unmet needs in the service offerings for
- 25:54Speaker 5: patients in leverage technology. Use technology to prove patient adherence, monitoring,
- 26:02Speaker 5: and communication, but not allowing it to replace the human touch.
- 26:07Speaker 5: The data can point you in a direction, it could
- 26:10Speaker 5: raise a flag of potential concern, but often the value
- 26:13Speaker 5: of a live clinical engagement can't be replaced. So use
- 26:17Speaker 5: technology where it makes sense to deliver a better patient
- 26:21Speaker 5: experience and optimize efficiency within operations, but don't fully replace
- 26:26Speaker 5: that patient engagement. Keep a patient centric approach, so focus
- 26:32Speaker 5: on understanding the individual needs of a patient in order
- 26:36Speaker 5: to offer holistic support that goes beyond just dispensing the medication.
- 26:41Speaker 5: And then, lastly, advocate for change. Be active in communities
- 26:45Speaker 5: and organizations such as NASP, working towards policy changes that
- 26:50Speaker 5: could improve access to treatments. Or reduce costs for patients
- 26:55Speaker 5: with rare disease. But focusing on these areas, I feel
- 27:00Speaker 5: pharmacists and healthcare leaders can significantly enhance the quality of
- 27:03Speaker 5: life of those living with these rare diseases.
- 27:08Speaker 3: Awesome, So so Jesse Michelle. If any of our listeners
- 27:11Speaker 3: have questions, how do they get in touch with you?
- 27:16Speaker 5: Yeah, and I think our website at masor dot com
- 27:21Speaker 5: master especially dot com Booth has an overview of our
- 27:23Speaker 5: company for max or on our services we offer, but
- 27:25Speaker 5: then drilling down into our rear disease products and services
- 27:28Speaker 5: that we offer. Michelle leads our business development on our
- 27:32Speaker 5: rear and orphan side, as well as my self leading operations.
- 27:35Speaker 5: So both of us are available. There's any questions reach
- 27:38Speaker 5: out to us as well.
- 27:40Speaker 3: Awesome. Well, thank you both Jessein and Michelle for chatting
- 27:43Speaker 3: with me and sharing this valuable information.
- 27:48Speaker 4: Of course it was our pleasure. Thank you for having us.
- 27:50Speaker 5: Sheila, thanks for having us today.
- 27:54Speaker 3: As a reminder, ANYSP corporate members are invited to be
- 27:57Speaker 3: my guest on one complimentary podcast per year. For more
- 28:00Speaker 3: information about this or other n e SP membership benefits
- 28:03Speaker 3: and events, please feel free to reach out to membership
- 28:07Speaker 3: at n A s p n e t dot org
- 28:10Speaker 3: or visit our website at www dot n A s
- 28:14Speaker 3: p n e t dot org. Until next time, have
- 28:18Speaker 3: a great day,